What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Hematology • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

This is becoming an increasingly thorny issue. A few guidelines to keep in mind:1) Dara-VRd has only been studied (thus far) in transplant-eligible patients. So this discussion of Dara-VRd vs. VRd is hard to apply to patients without intent for transplant. 2) When you look at the CASSIOPEIA and...

Comments

Medical Oncologist at Winship Cancer Institute of Emory University
I agree that the benefit of 4-drug induction is mo...

Medical Oncologist at ProMedica Flower Hospital
@Ben Derman, for patients with high risk cytogenet...

Medical Oncologist at University of Chicago
If the patient does not have significant neuropath...

Medical Oncologist at Upper Chesapeake Hematology Oncology
What do you offer for induction for a standard ris...

Medical Oncologist at Texas Oncology Dallas
What regimen do you favor in someone with newly di...

Related Questions